BioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2026 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.900-5.100 for the period, compared to the consensus earnings per share estimate of 4.800. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BMRN. Oppenheimer lifted their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a report on Friday. The Goldman Sachs Group initiated coverage on shares of BioMarin Pharmaceutical in a report on Monday, May 11th. They issued a “neutral” rating and a $69.00 price objective on the stock. Canaccord Genuity Group reduced their target price on shares of BioMarin Pharmaceutical from $116.00 to $111.00 and set a “buy” rating for the company in a report on Friday, May 22nd. Bank of America lowered their price target on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Finally, HC Wainwright upped their price objective on shares of BioMarin Pharmaceutical from $50.00 to $60.00 and gave the stock a “neutral” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average target price of $87.86.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $63.81 on Friday. The company has a market cap of $12.33 billion, a P/E ratio of 172.46, a P/E/G ratio of 0.47 and a beta of 0.24. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $66.28. The company’s 50-day moving average price is $58.19 and its 200-day moving average price is $57.06. The company has a current ratio of 5.81, a quick ratio of 4.20 and a debt-to-equity ratio of 0.23.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.36%. BioMarin Pharmaceutical’s quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, sell-side analysts forecast that BioMarin Pharmaceutical will post 4.22 earnings per share for the current fiscal year.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC boosted its position in shares of BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 179 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in BioMarin Pharmaceutical during the third quarter worth $40,000. Parallel Advisors LLC lifted its stake in BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 295 shares in the last quarter. Meeder Asset Management Inc. boosted its position in shares of BioMarin Pharmaceutical by 1,974.1% during the fourth quarter. Meeder Asset Management Inc. now owns 1,763 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,678 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at $201,000. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.